GAIN THERAPEUTICS, INC Repayments of Short-term Debt
GAIN THERAPEUTICS, INC (GANX) reported Repayments of Short-term Debt of $50.82 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfShortTermDebt · last filed 2026-08-11
- GAIN THERAPEUTICS, INC repayments of short-term debt for the quarter ending 2026-06-30 was $25.30K, a 4.37% increase year-over-year.
- GAIN THERAPEUTICS, INC repayments of short-term debt for the quarter ending 2026-03-31 was $25.52K, a 14.76% increase year-over-year.
- GAIN THERAPEUTICS, INC repayments of short-term debt for the quarter ending 2025-12-31 was $25.02K, a 9.86% increase year-over-year.
- GAIN THERAPEUTICS, INC repayments of short-term debt for the quarter ending 2025-09-30 was $25.00K, a 8.13% increase year-over-year.
- GAIN THERAPEUTICS, INC repayments of short-term debt for fiscal 2025 was $96.50K, a 6.19% increase from fiscal 2024.
- GAIN THERAPEUTICS, INC repayments of short-term debt for fiscal 2024 was $90.88K, a 2.03% increase from fiscal 2023.
- GAIN THERAPEUTICS, INC repayments of short-term debt for fiscal 2023 was $89.07K, a 13.07% increase from fiscal 2022.
- GAIN THERAPEUTICS, INC repayments of short-term debt for fiscal 2022 was $78.77K, a 258.86% increase from fiscal 2021.
| Period end | Repayments of Short-term Debt 3 month | Repayments of Short-term Debt 6 month | Repayments of Short-term Debt 9 month | Repayments of Short-term Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $25.30K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $50.82K 10-Q · filed 2026-08-11 | $75.85K derived: sum of 3 quarters · filed 2026-08-11 | $100.84K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $25.52K 10-Q · filed 2026-05-11 | $50.55K derived: sum of 2 quarters · filed 2026-05-11 | $75.55K derived: sum of 3 quarters · filed 2026-05-11 | $99.78K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $25.02K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $50.02K derived: sum of 2 quarters · filed 2026-03-26 | $74.26K derived: sum of 3 quarters · filed 2026-08-11 | $96.50K 10-K · filed 2026-03-26 |
| 2025-09-30 | $25.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $49.23K derived: sum of 2 quarters · filed 2026-08-11 | $71.48K 10-Q · filed 2025-11-12 | $94.26K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $24.24K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $46.48K 10-Q · filed 2026-08-11 | $69.26K derived: sum of 3 quarters · filed 2026-08-11 | $92.38K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $22.24K 10-Q · filed 2026-05-11 | $45.02K derived: sum of 2 quarters · filed 2026-05-11 | $68.14K derived: sum of 3 quarters · filed 2026-05-11 | $90.25K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $22.78K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $45.90K derived: sum of 2 quarters · filed 2026-03-26 | $68.01K derived: sum of 3 quarters · filed 2026-03-26 | $90.88K 10-K · filed 2026-03-26 |
| 2024-09-30 | $23.12K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $45.23K derived: sum of 2 quarters · filed 2025-11-12 | $68.10K 10-Q · filed 2025-11-12 | $90.68K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $22.11K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $44.98K 10-Q · filed 2025-08-12 | $67.56K derived: sum of 3 quarters · filed 2025-08-12 | $90.19K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $22.87K 10-Q · filed 2025-05-14 | $45.45K derived: sum of 2 quarters · filed 2025-05-14 | $68.08K derived: sum of 3 quarters · filed 2025-05-14 | $90.33K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $22.58K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $45.21K derived: sum of 2 quarters · filed 2025-03-27 | $67.45K derived: sum of 3 quarters · filed 2025-03-27 | $89.07K 10-K · filed 2025-03-27 |
| 2023-09-30 | $22.63K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $44.88K derived: sum of 2 quarters · filed 2024-11-14 | $66.49K 10-Q · filed 2024-11-14 | $88.07K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $22.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $43.86K 10-Q · filed 2024-08-08 | $65.44K derived: sum of 3 quarters · filed 2024-08-08 | $86.02K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $21.61K 10-Q · filed 2024-05-14 | $43.19K derived: sum of 2 quarters · filed 2024-05-14 | $63.77K derived: sum of 3 quarters · filed 2024-05-14 | $62.41K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $21.58K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $42.16K derived: sum of 2 quarters · filed 2024-03-26 | $40.80K derived: sum of 3 quarters · filed 2024-03-26 | $78.77K 10-K · filed 2024-03-26 |
| 2022-09-30 | $20.58K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $19.22K derived: sum of 2 quarters · filed 2023-11-14 | $57.19K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | -$1.36K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $36.61K 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $37.97K 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | $21.95K 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |